Millennium Management’s Blueprint Medicines BPMC Stock Holding History

Millennium Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,900	Closed	-$4.86M	–	6039
2025 Q2	$4.86M	Buy	+37,900	New	+$3.94M	﹤0.01%	3031
2022 Q3	–	Sell	-46,400	Closed	-$2.34M	–	7071
2022 Q2	$2.34M	Buy	+46,400	New	+$2.72M	﹤0.01%	3533
2019 Q3	–	Sell	-200,000	Closed	-$18.9M	–	4176
2019 Q2	$18.9M	Buy	200,000 +100,000	+100%	+$8.25M	0.03%	831
2019 Q1	$8.01M	Buy	+100,000	New	+$7.39M	0.01%	1425

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Millennium Management's BPMC Position: Q3 2025 in Review

Millennium Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 295,879 shares — an estimated $37.9M sold.

Millennium Management first reported a position in BPMC in Q2 2015 and held it in 32 quarters. The position peaked at $67.6M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Millennium Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Millennium Management sold 295,879 Blueprint Medicines shares in Q3 2025, an estimated $37.9M.
Millennium Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 32 quarters.
Millennium Management's Blueprint Medicines position peaked at $67.6M in Q2 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.